​brain_photobiomodulation-preliminary_results_from_.pdf

The above article supports the value of low-level infrared light stimulation using sophisticated blood oxygenation and imaging technology. We used similar though less advanced tools in our 2012 study 28 days of 6-minute, transcranial and intraocular 1065-1075nm photobiomodulation of subjects struggling with probable Alzheimer's disease.  The current study using the same device is now 56-days with more powerful lLED stimulation. 

This recent article by my colleague Michael Hambin, PhD offers a well organized and rather complete review of the current state of the science related to the clinical application of low level light stimulation. The edited volume on the subject Photobiomodulation and the Brain has recently been published by Elsevier and contains a chapter on the integration of neurofeedback photobiomodulation by myself, Trent Nichols, MD and our colleagues Jason Huang MD and Damir Nizmutdiinov MD PhD from Baylor Scott & White Research Institute.  

We are seeing terrific results within our clinic using these tools and are excited by the future applications that are being created based on this and other research. 

Our approach to treatment is aligned with Dr. Perlmutter, Bredesen and supports the Institute for Functional Medicine's model for clinical intervention by boosting the capacity for recovery and healing. Photobiomodulation stimulates mitochondria to produce more ATP and thereby improve the brain's ability to function efficiently. Neurofeedback adds an important component to this process by improving the neural connectivity that allows for continued improvement by having renormalized brain network functioning. Functional medicine works to remove the underlying bacterial, viral and toxic contributors to neurophysiological deterioration.

globallymealliance.org/top-7-science-based-events-to-impact-lyme-disease-in-2018/​

There's​ growing evidence that the underlying cause of dementia is not the beta amyloid proteins that then develop into plaques that can interfere within neurons communicating efficiently. New thinking by Rudy Tanzi and Robert Moir and others now suggests that amyloid activity is part of the earliest forms of our immune system. Our work with neurofeedback and photobiomodulation supports this way of thinking as it refocuses attention at the system level where many factors can be considered 'causal' in the deterioration of synaptic communication. This leads to thinking more broadly and creatively about intervention strategies that include non-drug, noninvasive technologies like neurofeedback and infrared light therapy. The following discussion provides a context for how they arrived at this new view of beta amyloid as not the primal generator in neurodegeneration. 

www.npr.org/sections/health-shots/2018/02/18/580475245/scientists-explore-ties-between-alzheimers-and-brains-ancient-immune-system

​About a year ago I read an article in the AARP magazine about a study being done with the use of Vielight for depression and Alzheimer’s.  I was so excited to read about it because 10 years ago my mother had been diagnosed with Alzheimer’s and soon she would be moving here to Tennessee where there would be more family support for her with my sister who also moved here and one of our brother’s living here.  My husband and I did a lot of research and were determined God had given us an answer to my mom’s disease. But we were not sure we could make the investment.
 
In February my mom moved in with us. My husband and I were overwhelmed with all that came at us. All that we had been warned about by our doctor friends was happening.  She was aggressive, confused, escaping in the middle of the night and very scared.  That was it we had to have the Vielight.  We contacted Dr. Berman and as soon as we received the Vielight I got on the phone with him and did a skype call so he could show me the positions I needed to use and start the therapy.
 
I am excited to tell you that my mom now lives in her own home (with full time care takers of course).  She is happy and very active.  She volunteers with her caretaker at a local thrift store and realizes she lives in a very peaceful community in Tennessee.  She talks to her friends on the phone and is able to share with us how her friends are doing after having a conversation with them.  She still shows signs of the disease but I believe that we have halted the progression and may even turned but the clock on the bloody thing.
 
We hope to have my mom with us a very long time.  She has no other medical issues and the Vielight has been an answer to prayers.
 

​The placebo effect has solid neurophysiological and biochemical roots that need to be appreciated for their direct influence over clinical outcomes, i.e., recovery of functioning and healing. Psychotherapy and neurofeedback and all the 'softer' (noninvasive) interventions now can be better understood for their role in treatment. 
 
www.nytimes.com/2018/11/07/magazine/placebo-effect-medicine.html

https://neurosciencenews.com/inflammation-alzheimers-10061/
​